All In Biotech

Drug Trial Radar · NCT00853658

Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure

A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity and Mortality in Patients With Chronic Heart Failure (NYHA Class II - IV). The Study is Also Known as Aliskiren Trial of Minimizing OutcomeS in Patients With HEart Failure (ATMOSPHERE).

Last checked: Nov 19, 2026Latest source record: Nov 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 7,064 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7,064

Actual

Start

Mar 2009

Primary completion

Oct 2015

Study completion Oct 2015

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 2, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV.

Conditions

  • Chronic Heart Failure

Interventions

  • EnalaprilDrug

    Enalapril 10 mg film-coated tablet and administered orally.

  • AliskirenDrug

    Aliskiren 150 mg titrated to 300 mg film-coated tablet and administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) HospitalizationTime frame: up to End of Study (78 months)

Locations

806 sites in 44 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Huntsville, Alabama

  • Novartis Investigative Site

    Mobile, Alabama

  • Novartis Investigative Site

    Mobile, Alabama

  • Novartis Investigative Site

    Tucson, Arizona

  • Novartis Investigative Site

    Hot Springs, Arkansas

  • Novartis Investigative Site

    Little Rock, Arkansas

  • Novartis Investigative Site

    Little Rock, Arkansas

  • Novartis Investigative Site

    Pine Bluff, Arkansas

  • Novartis Investigative Site

    Searcy, Arkansas

  • Novartis Investigative Site

    Beverly Hills, California

  • Novartis Investigative Site

    French Camp, California

  • Novartis Investigative Site

    Inglewood, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Modesto, California

  • Novartis Investigative Site

    Northridge, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    Santa Monica, California

  • Novartis Investigative Site

    Westlake Village, California

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Littleton, Colorado

  • Novartis Investigative Site

    Boynton Beach, Florida

  • Novartis Investigative Site

    Daytona Beach, Florida

  • Novartis Investigative Site

    Fort Lauderdale, Florida

  • Novartis Investigative Site

    Hollywood, Florida

  • Novartis Investigative Site

    Jacksonville Beach, Florida

  • Novartis Investigative Site

    Miami Lakes, Florida

  • Novartis Investigative Site

    Orlando, Florida

  • Novartis Investigative Site

    Wellington, Florida

  • Novartis Investigative Site

    Athens, Georgia

  • Novartis Investigative Site

    Augusta, Georgia

  • Novartis Investigative Site

    Gillespie, Illinois

  • Novartis Investigative Site

    Topeka, Kansas

  • Novartis Investigative Site

    Metairie, Louisiana

  • Novartis Investigative Site

    New Orleans, Louisiana

  • Novartis Investigative Site

    Slidell, Louisiana

  • Novartis Investigative Site

    Auburn, Maine

  • Novartis Investigative Site

    Southfield, Michigan

  • Novartis Investigative Site

    St Louis, Missouri

  • Novartis Investigative Site

    Lincoln, Nebraska

Showing 40 of 806 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.